Mezencev R - Search Results

1

Targeted removal of migratory tumor cells by functionalized magnetic nanoparticles impedes metastasis and tumor progression.

Scarberry KE, Mezencev R, McDonald JF. Scarberry KE, et al. Among authors: mezencev r. Nanomedicine (Lond). 2011 Jan;6(1):69-78. doi: 10.2217/nnm.10.103. Nanomedicine (Lond). 2011. PMID: 21182419

2

Targeted in vivo delivery of EGFR siRNA inhibits ovarian cancer growth and enhances drug sensitivity.

Satpathy M, Mezencev R, Wang L, McDonald JF. Satpathy M, et al. Among authors: mezencev r. Sci Rep. 2016 Nov 7;6:36518. doi: 10.1038/srep36518. Sci Rep. 2016. PMID: 27819259 Free PMC article.

3

Interactions of cisplatin with non-DNA targets and their influence on anticancer activity and drug toxicity: the complex world of the platinum complex.

Mezencev R. Mezencev R. Curr Cancer Drug Targets. 2015;14(9):794-816. doi: 10.2174/1568009614666141128105146. Curr Cancer Drug Targets. 2015. PMID: 25431081 Review.

4

Isolation and characterization of stem-like cells from a human ovarian cancer cell line.

Wang L, Mezencev R, Bowen NJ, Matyunina LV, McDonald JF. Wang L, et al. Among authors: mezencev r. Mol Cell Biochem. 2012 Apr;363(1-2):257-68. doi: 10.1007/s11010-011-1178-6. Epub 2011 Dec 9. Mol Cell Biochem. 2012. PMID: 22160925

5

Rapid mass spectrometric metabolic profiling of blood sera detects ovarian cancer with high accuracy.

Zhou M, Guan W, Walker LD, Mezencev R, Benigno BB, Gray A, Fernández FM, McDonald JF. Zhou M, et al. Among authors: mezencev r. Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2262-71. doi: 10.1158/1055-9965.EPI-10-0126. Epub 2010 Aug 10. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20699376

6

Cell stiffness is a biomarker of the metastatic potential of ovarian cancer cells.

Xu W, Mezencev R, Kim B, Wang L, McDonald J, Sulchek T. Xu W, et al. Among authors: mezencev r. PLoS One. 2012;7(10):e46609. doi: 10.1371/journal.pone.0046609. Epub 2012 Oct 4. PLoS One. 2012. PMID: 23056368 Free PMC article.

7

OVCAR-3 spheroid-derived cells display distinct metabolic profiles.

Vermeersch KA, Wang L, Mezencev R, McDonald JF, Styczynski MP. Vermeersch KA, et al. Among authors: mezencev r. PLoS One. 2015 Feb 17;10(2):e0118262. doi: 10.1371/journal.pone.0118262. eCollection 2015. PLoS One. 2015. PMID: 25688563 Free PMC article.

8

Delivery of siRNA to ovarian cancer cells using laser-activated carbon nanoparticles.

Sengupta A, Mezencev R, McDonald JF, Prausnitz MR. Sengupta A, et al. Among authors: mezencev r. Nanomedicine (Lond). 2015;10(11):1775-84. doi: 10.2217/nnm.15.27. Nanomedicine (Lond). 2015. PMID: 26080699 Free PMC article.

9

Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells.

Wang L, Mezencev R, Švajdler M, Benigno BB, McDonald JF. Wang L, et al. Among authors: mezencev r. Gynecol Oncol. 2014 Jul;134(1):96-103. doi: 10.1016/j.ygyno.2014.04.055. Epub 2014 May 4. Gynecol Oncol. 2014. PMID: 24802724

10

Highly-accurate metabolomic detection of early-stage ovarian cancer.

Gaul DA, Mezencev R, Long TQ, Jones CM, Benigno BB, Gray A, Fernández FM, McDonald JF. Gaul DA, et al. Among authors: mezencev r. Sci Rep. 2015 Nov 17;5:16351. doi: 10.1038/srep16351. Sci Rep. 2015. PMID: 26573008 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results